膀胱癌化疗药物增敏机制研究进展  

Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer

作　　者：徐伟平 周维英 XU Weiping;ZHOU Weiying(Southwest University of Political Science and Law Hospital,Chongqing 401120,China;Department of Pharmacology,Chongqing Medical University,Chongqing 401120,China;Chongqing Key Laboratory of Drug Metabolism,Chongqing 400016,China;Chongqing Laboratory of Biochemisty and Molecular Pharmacology,Chongqing 401120,China)

机构地区：[1]西南政法大学校医院,重庆401120 [2]重庆医科大学药学院药理学教研室,重庆400016 [3]重庆医科大学药学院药物代谢研究重庆市重点实验室,重庆400016 [4]重庆医科大学药学院重庆市生物化学与分子药理学实验室,重庆400016

出　　处：《中国临床药理学与治疗学》2019年第9期1060-1064,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金面上项目(81874100)

摘　　要：近年来化疗耐药严重制约着膀胱癌的治疗效果,术后复发率和转移率居高不下。因此,逆转膀胱癌化疗耐药性,寻找有效的化疗增敏靶点并探究其机制十分重要。目前临床上多采用经尿道膀胱肿瘤切除术,术后选择辅助化疗药物进行治疗,常用化疗药物包括顺铂、吉西他滨、阿霉素、表柔比星等。目前实现这些药物化疗增敏的靶点基因和分子在膀胱癌细胞中呈现不同的表达状态,且通过这些靶点实现增敏的机制也各有不同。本文将就膀胱癌化疗药物增敏靶点及机制的研究进展进行综述,以期为膀胱癌的化疗增敏探索新的思路。In recent years,chemoresistance has seriously restricted the therapeutic effect of bladder cancer,and the recurrence rate and metastasis rate remain high.Therefore,it is very important to reverse the resistance of bladder cancer to chemotherapy,and find more effective target of chemosensitizion and explore its mechanism.Transurethral resection of bladder tumors is commonly used in treatment of bladder cancer currently,and adjuvant chemotherapy drugs are utilized after operation.The most chemotherapy drugs used in bladder cancer include cisplatin,gemcitabine,adriamycin and epirubicin.At present,the target genes and molecules for enhancing chemosensitivity of these drugs display various expression states in bladder cancer cells,and the mechanisms for enhancing chemosensitivity through these targets are also different.In this paper,we will review the research progress of target and mechanism of chemosensitizing drugs for bladder cancer,and explore new ideas for chemosensitizion of bladder cancer.

关 键 词：膀胱癌 耐药 化疗药物 化疗增敏 靶点 

分 类 号：R737[医药卫生—肿瘤] R69[医药卫生—临床医学]